Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Top Stories > Novavax shares sink premarket as going concern worries weigh
    Top Stories

    Novavax shares sink premarket as going concern worries weigh

    Published by Uma Rajagopal

    Posted on March 1, 2023

    2 min read

    Last updated: February 2, 2026

    Illustration featuring syringes beside the Novavax logo, reflecting the company's recent stock decline due to concerns about its COVID-19 vaccine and business sustainability.
    Syringes and Novavax logo illustration highlighting COVID-19 vaccine concerns - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:stockfinancial crisisinvestmentmarket capitalisationcorporate governance

    Quick Summary

    (Reuters) -Novavax Inc’s shares plunged more than 24% in U.S. premarket trading on Wednesday, a day after the COVID-19 vaccine maker raised doubts about its ability to remain in

    (Reuters) -Novavax Inc’s shares plunged more than 24% in U.S. premarket trading on Wednesday, a day after the COVID-19 vaccine maker raised doubts about its ability to remain in business.

    The stock dropped as much as 24.4% to $7.0 by 5:30 a.m. ET (1030 am GMT), while its Frankfurt-listed shares fell 24.8%.

    The company, which reported fourth-quarter earnings late on Tuesday, flagged significant uncertainty around its 2023 revenue and said that the U.S. government had not extended its agreement to buy its shots beyond December this year.

    The going-concern disclosure is driven by near-term uncertainties, such as Novavax’s ability to deliver a variant-adaptive vaccine in time and grants from the U.S. government, said Jefferies analyst Rogers Song.

    “While we continue to see sustained value from Novavax’s protein-based vaccine for the long run, we note a few key near-term uncertainties…leading to one-year going-concern disclosure,” Song said in a research note.

    Novavax’s COVID-19 vaccine had been expected to convince those skeptical about mRNA shots from rivals Moderna and Pfizer to get immunized, but the vaccine has been plagued by manufacturing and regulatory delays as well as sluggish uptake in key markets.

    As of March 1, only 79,668 doses of Novavax’s vaccine were received by people in the United States, according to latest government data. The shot is the company’s first marketed product, after more than 35 years in business.

    Shares of the company lost nearly 93% in value last year, marking their worst yearly performance on record. While the stock rose 6% in January this year, it posted its biggest February percentage loss since 2019.

    As of last close, the vaccine maker’s U.S.-listed shares are down 97% from their February 2021 record high of $331.68.

    (Reporting by Amanda Cooper in London, Amruta Khandekar and Bhanvi Satija in Bengaluru; Editing by Danilo Masoni and Uttaresh Venkateshwaran)

    Frequently Asked Questions about Novavax shares sink premarket as going concern worries weigh

    1What is a going concern?

    A going concern is an accounting term that indicates a company is expected to continue its operations for the foreseeable future, typically at least one year from the date of the financial statements.

    2What are fourth-quarter earnings?

    Fourth-quarter earnings refer to a company's financial performance during the last quarter of its fiscal year, which is often used to assess its overall annual performance.

    3What is market capitalisation?

    Market capitalisation is the total market value of a company's outstanding shares of stock, calculated by multiplying the share price by the total number of shares.

    More from Top Stories

    Explore more articles in the Top Stories category

    Image for Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Image for Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Image for Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Image for Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Image for Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Image for Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Image for Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Image for PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    Image for A Notable Update for Employee Health Benefits:
    A Notable Update for Employee Health Benefits:
    Image for Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Image for Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Image for ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    View All Top Stories Posts
    Previous Top Stories PostPuma expects cost pressure on margins to persist in 2023
    Next Top Stories PostJulius Baer completes share buy-back programme